Correlations between disease-free survival (DFS) and overall survival (OS) in patients (pts) with renal cell carcinoma (RCC) at high risk for recurrence: Results from S-TRAC trial

被引：0
|
作者：
George, D. J. [1 ]
Pantuck, A. J. [2 ]
Figlin, R. [3 ]
Escudier, B. [4 ]
Halabi, S. [5 ]
Casey, M. [6 ]
Lin, X. [7 ]
Serfass, L. [8 ]
Frean, M. J. Lechuga [9 ]
Ravaud, A. [10 ]
机构：
[1] Duke Univ, Med Ctr, Div Oncol, Durham, NC USA
[2] Ronald Reagan UCLA Med Ctr, Dept Urol, Los Angeles, CA USA
[3] Cedars Sinai Med Ctr, Med Hematol Oncol, Los Angeles, CA 90048 USA
[4] Gustave Roussy Inst Cancerol, Dept Med Oncol, Villejuif, France
[5] Duke Univ, Biostat & Bioinformat, Durham, NC USA
[6] Pfizer Inc, Dept Oncol, Collegeville, PA USA
[7] Pfizer Inc, Oncol, La Jolla, CA USA
[8] Pfizer, Med, Paris, France
[9] Pfizer, Oncol, Milan, Italy
[10] Hop St Andre, CHU Bordeaux, Dept Med Oncol, Bordeaux, France
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
881P
引用
收藏
页码：312 / 312
页数：1
相关论文
共 50 条
  • [21] Overall Survival (OS) in Meteor, A Randomised Phase III Trial of Cabozantinib Versus Everolimus in Patients with Advanced Renal Cell Carcinoma (RCC)
    Mainwaring, Paul
    Powles, Thomas
    Escudier, Bernard J.
    Tannir, Nizar M.
    Rini, Brian I.
    Hammers, Hans J.
    Donskov, Frede
    Roth, Bruce J.
    Peltola, Katriina
    Lee, Jae-Lyun
    Heng, Daniel Yick Chin
    Schmidinger, Manuela
    Aftab, Dana T.
    Hessel, Colin
    Scheffold, Christian
    Schwab, Gisela
    Pal, Sumanta K.
    Hutson, Thomas E.
    Motzer, Robert J.
    Choueiri, Toni K.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 : 109 - 109
  • [22] Evaluation of disease-free survival as an intermediate metric for overall survival in localized renal cell carcinoma: A trial-level meta-analysis
    Harshman, Lauren Christine
    Xie, Wanling
    Moreira, Raphael Brandao
    Bosse, Dominick
    Ares, Gustavo Ruiz
    Sweeney, Christopher
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [23] Effect of bisphosphonates (Bis) combined with sunitinib (Su) on the response rate (RR), progression-free survival (PFS), and overall survival (OS) of patients (pts) with bone metastases (mets) from renal cell carcinoma (RCC).
    Keizman, Daniel
    Ish-Shalom, Maya
    Taksey, Jason David
    Pili, Roberto
    Hammers, Hans J.
    Eisenberger, Mario A.
    Boursi, Ben
    Berger, Raanan
    Maimon, Natalie
    Gottfried, Maya
    Hayat, Henry
    Peer, Avivit
    Kovel, Svetlana
    Sella, Avishay
    Carducci, Michael Anthony
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [24] Exploring Biological Predictive Factors of Progression After Surgery in High-Risk Renal Cell Carcinoma: Results From the French Cohort of the Randomized S-TRAC Trial Patients
    Ouzaid, Idir
    Kammerer-Jacquet, Solene Florence
    Khene, Zineddine
    Ravaud, Alain
    Patard, Jean-Jacques
    Bensalah, Karim
    Rioux-Leclercq, Nathalie
    FRONTIERS IN SURGERY, 2020, 7
  • [25] ASSESSING THE VIABILITY OF A SURROGACY RELATIONSHIP BETWEEN DISEASE-FREE SURVIVAL (DFS) AND OVERALL SURVIVAL (OS) FOR THE PATIENTS IN CLINICAL TRIALS FOR ADJUVANT TREATMENT OF MUSCLE-INVASIVE UROTHELIAL CARCINOMA (MIUC) FOLLOWING RADICAL CYSTECTOMY
    Barkema, A. E.
    Simons, C.
    Kurt, M.
    Broughton, E.
    Teitsson, S.
    May, J. R.
    Kroep, S.
    VALUE IN HEALTH, 2022, 25 (01) : S203 - S203
  • [26] Use of bisphosphonates (Bis) combined with sunitinib (Su) to improve the response rate (RR), progression-free survival (PFS), and overall survival (OS) of patients (pts) with bone metastases (mets) from renal cell carcinoma (RCC)
    Peer, Avivit
    Ish-Shalom, Maya
    Hammers, Hans J.
    Eisenberger, Mario A.
    Sinibaldi, Victoria J.
    Pili, Roberto
    Maimon, Natalie
    Gottfried, Maya
    Hayat, Henry
    Kovel, Svetlana
    Sella, Avishay
    Neumann, Avivit
    Boursi, Ben
    Berger, Raanan
    Carducci, Michael Anthony
    Keizman, Daniel
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [27] Prevalence, Disease-free, and Overall Survival of Contemporary Patients With Renal Cell Carcinoma Eligible for Adjuvant Checkpoint Inhibitor Trials
    Marconi, Lorenzo
    Sun, Maxine
    Beisland, Christian
    Klatte, Tobias
    Ljungberg, Boerje
    Stewart, Grant D.
    Dabestani, Saeed
    Choueiri, Toni K.
    Bex, Axel
    CLINICAL GENITOURINARY CANCER, 2021, 19 (02) : E92 - +
  • [28] Phase III trial of sunitinib (SU) vs placebo (PBO) as adjuvant treatment for high-risk renal cell carcinoma (RCC) after nephrectomy (S-TRAC)
    Ravaud, A.
    Motzer, R. J.
    Pandha, H. S.
    Staehler, M.
    George, D.
    Pantuck, A. J.
    Patel, A.
    Chang, Y-H.
    Escudier, B.
    Donskov, F.
    Magheli, A.
    Carteni, G.
    Laguerre, B.
    Tomczak, P.
    Breza, J.
    Gerletti, P.
    Lin, X.
    Lechuga, M.
    Martini, J-F.
    Patard, J-J.
    ANNALS OF ONCOLOGY, 2016, 27
  • [29] EVALUATING DISEASE-FREE SURVIVAL (DFS) AS A SURROGATE ENDPOINT (SE) FOR OVERALL SURVIVAL (OS) IN MUSCLE-INVASIVE UROTHELIAL CARCINOMA (MIUC): AN ANALYSIS OF SURVEILLANCE, EPIDEMIOLOGY, AND END RESULTS (SEER)-MEDICARE DATA
    Leung, L.
    Kanters, S.
    Pourrahmat, M. M.
    Friedman, H. S.
    Navaratnam, P.
    Reardon, G.
    Patel, M. Y.
    Teitsson, S.
    Kurt, M.
    Lotan, Y.
    VALUE IN HEALTH, 2023, 26 (06) : S54 - S54
  • [30] Identification of predictive biomarkers of overall survival (OS) in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (I) with or without bevacizumab (B): Results from CALGB 90206 (Alliance)
    Nixon, Andrew B.
    Halabi, Susan
    Shterev, Ivo
    Starr, Mark
    Brady, John C.
    Dutcher, Janice P.
    Hopkins, Judith O.
    Hurwitz, Herbert
    Small, Eric Jay
    Rini, Brian I.
    Febbo, Phillip G.
    George, Daniel J.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
12345